AlgeriaTuberculosis profile
Population  2015 40 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.2 (2.1–4.6) 8.2 (5.3–12)
Mortality (HIV+TB only) 0.035 (<0.01–0.13) 0.09 (0–0.32)
Incidence  (includes HIV+TB) 30 (23–37) 75 (58–94)
Incidence (HIV+TB only) 0.2 (0.14–0.27) 0.51 (0.36–0.68)
Incidence (MDR/RR-TB)** 0.47 (0.14–0.8) 1.2 (0.35–2)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 2 (1.4–2.6) 11 (6.8–15) 13 (8.2–17)
Males 0.9 (0.57–1.2) 16 (12–20) 17 (13–21)
Total 2.9 (2–3.8) 27 (23–31) 30 (23–37)
TB case notifications, 2015  
Total cases notified 23 879
Total new and relapse 23 705
          - % tested with rapid diagnostics at time of diagnosis <1%
          - % with known HIV status  
          - % pulmonary 36%
          - % bacteriologically confirmed among pulmonary 85%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.11 (0.07–0.17)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  160
(49–270)
Estimated % of TB cases with MDR/RR-TB 1.4% (0.33–2.5) 9.1% (0–23)  
% notified tested for rifampicin resistance 2% 42% 713
MDR/RR-TB cases tested for resistance to second-line drugs   23
Laboratory-confirmed cases MDR/RR-TB: 63, XDR-TB: 11
Patients started on treatment **** MDR/RR-TB: 94, XDR-TB: 11
Treatment success rate and cohort size Success Cohort
New cases registered in 2014 88% 6 765
Previously treated cases registered in 2014 57% 167
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data